Evoke Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Evoke Pharma generated cash of -$4,984,977, which is more than the previous year. Cash used in financing activities reached the amount of -$119,296 last year. Net change in cash is therefore -$5,104,273.
Cash Flow
| 2014 | -11.50M | 0 | 1.46M |
|---|---|---|---|
| 2015 | -10.49M | 0 | 5.03M |
| 2016 | -8.70M | 0 | 9.02M |
| 2017 | -8.71M | 0 | 7.38M |
| 2018 | -6.97M | 0 | 4.61M |
| 2019 | -5.76M | 0 | 6.10M |
| 2020 | -6.63M | 0 | 9.03M |
| 2021 | -12.35M | 0 | 13.42M |
| 2022 | -6.59M | 0 | 7.29M |
| 2023 | -4.98M | 0 | -119.29K |
EVOK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.84M | 9.14M | 8.06M | 5.66M | 5.31M | 7.67M | 9.00M | 8.69M | 14.15M | 24.19M |
Operating activities | ||||||||||
Net income | -7.79M | -8.22M | -8.53M | -13.15M | -7.12M | -7.56M | -12.22M | -10.74M | -12.12M | -13.24M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 1.12M | 1.45M | 1.87M | 1.62M | 1.37M | 0 | 1.81M | 1.70M | 1.50M | 1.10M |
| Deferred income tax benefit | 1.12M | 1.45M | 1.87M | 1.62M | 1.37M | 0 | 1.81M | 1.70M | 1.50M | 1.10M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -48.23K | -329.63K | -271.88K | 4.60M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -192.46K | -103.84K | 20.94K | -236.48K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 655.12K | 60.28K | -527.85K | 416.42K | 106.28K | -440.38K | 663.16K | -276.71K | -20.48K | 866.56K |
Cash generated by operating activities | -4.98M | -6.59M | -12.35M | -6.63M | -5.76M | -6.97M | -8.71M | -8.70M | -10.49M | -11.50M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | -119.29K | 7.44M | 13.42M | 3.59M | 6.10M | 4.61M | 7.38M | 13.52M | 5.03M | 42.87K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 119.41K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -5.10M | 0 | 0 | 0 | -4.5M | 0 | -3M |
Cash used in financing activities | -119.29K | 7.29M | 13.42M | 9.03M | 6.10M | 4.61M | 7.38M | 9.02M | 5.03M | 1.46M |
Net Change In Cash | -5.10M | 698.98K | 1.07M | 2.40M | 344.82K | -2.36M | -1.32M | 315.91K | -5.46M | -10.04M |
Cash at end of period | 4.73M | 9.84M | 9.14M | 8.06M | 5.66M | 5.31M | 7.67M | 9.00M | 8.69M | 14.15M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |